{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:09:32Z","timestamp":1779973772775,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40290-026-00610-4","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T12:03:03Z","timestamp":1778414583000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-2029","authenticated-orcid":false,"given":"Susan M.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4882-6383","authenticated-orcid":false,"given":"Caleb","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-2831","authenticated-orcid":false,"given":"Niquiche","family":"Guity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-9301","authenticated-orcid":false,"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7611-217X","authenticated-orcid":false,"given":"Lynne","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"610_CR1","unstructured":"Pediatric Research Equity Act of 2003. Pub. L. No. 108-155. https:\/\/www.congress.gov\/bill\/108th-congress\/senate-bill\/650. Accessed 25 Feb 2026."},{"key":"610_CR2","unstructured":"Food and Drug Administration Amendments Act of 2007. Pub. L. No. 110-85. https:\/\/www.congress.gov\/bill\/110th-congress\/house-bill\/3580\/text. Accessed 25 Feb 2026."},{"key":"610_CR3","unstructured":"U.S. Food and Drug Administration. Guidance document pediatric drug development under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: scientific considerations. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pediatric-drug-development-under-pediatric-research-equity-act-and-best-pharmaceuticals-children-act. Accessed 10 Feb 2025."},{"issue":"11","key":"610_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jamainternmed.2022.4226","volume":"182","author":"BL Brown","year":"2022","unstructured":"Brown BL, Mitra-Majumdar M, Darrow JJ, Moneer O, Pham C, Avorn J, et al. Fulfillment of postmarket commitments and requirements for new drugs approved by the FDA, 2013-2016. JAMA Intern Med. 2022;182(11):1223\u20136. https:\/\/doi.org\/10.1001\/jamainternmed.2022.4226.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"610_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5725","volume":"33","author":"L Choi","year":"2024","unstructured":"Choi L, Etchey B, Billings M, Lee C, Weil KM, Boxwell D, et al. A descriptive analysis of postmarketing requirement studies and clinical trials. Pharmacoepidemiol Drug Saf. 2024;33(1):e5725. https:\/\/doi.org\/10.1002\/pds.5725.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"610_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40264-022-01152-9","volume":"45","author":"O Moneer","year":"2022","unstructured":"Moneer O, Brown BL, Avorn J, Darrow JJ, Mitra-Majumdar M, Joyce KW, et al. New drug postmarketing requirements and commitments in the US: A systematic review of the evidence. Drug Saf. 2022;45(4):305\u201318. https:\/\/doi.org\/10.1007\/s40264-022-01152-9.","journal-title":"Drug Saf"},{"key":"610_CR7","unstructured":"U.S. Department of Health and Human Services, Office of Inspector General. FDA's Monitoring of Postmarketing Study Commitments. 2006. https:\/\/oig.hhs.gov\/reports\/all\/2006\/fdas-monitoring-of-postmarketing-study-commitments\/. Accessed 7 Aug 2025."},{"key":"610_CR8","unstructured":"U.S. Department of Health and Human Services, Office of Inspector General. FDA is issuing more postmarketing requirements, but challenges with oversight persist. 2016. https:\/\/oig.hhs.gov\/reports\/all\/2016\/fda-is-issuing-more-postmarketing-requirements-but-challenges-with-oversight-persist\/. Accessed 6 Aug 2025."},{"issue":"12","key":"610_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMp1705800","volume":"377","author":"S Woloshin","year":"2017","unstructured":"Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med. 2017;377(12):1114\u20137. https:\/\/doi.org\/10.1056\/NEJMp1705800.","journal-title":"N Engl J Med"},{"key":"610_CR10","doi-asserted-by":"publisher","unstructured":"Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA); Board on Health Sciences Policy; Institute of Medicine. Safe and effective medicines for children: pediatric studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. In: Field MJ, Boat TF, editors. Washington (DC): National Academies Press (US); 2012. https:\/\/doi.org\/10.17226\/13311(PMID: 24872968).","DOI":"10.17226\/13311"},{"key":"610_CR11","unstructured":"U.S. Food and Drug Administration. Pediatric tracking requirements under FDAAA. https:\/\/www.fda.gov\/science-research\/pediatrics\/pediatric-tracking-requirements-under-fdaaa. Accessed 9 Aug 2025."},{"key":"610_CR12","unstructured":"U.S. Food and Drug Administration. Pediatric labeling changes. https:\/\/www.fda.gov\/science-research\/pediatrics\/pediatric-labeling-changes. Accessed 9 Aug 2025."},{"issue":"1","key":"610_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","volume":"173","author":"TJ Hwang","year":"2019","unstructured":"Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT. Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act. JAMA Pediatr. 2019;173(1):68\u201374. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.3416.","journal-title":"JAMA Pediatr"},{"issue":"12","key":"610_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018587","volume":"7","author":"JD Zeitoun","year":"2017","unstructured":"Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, et al. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study. BMJ Open. 2017;7(12):e018587. https:\/\/doi.org\/10.1136\/bmjopen-2017-018587.","journal-title":"BMJ Open"},{"issue":"5","key":"610_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3410","volume":"2","author":"JJ Skydel","year":"2019","unstructured":"Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD. Analysis of postapproval clinical trials of therapeutics approved by the US Food and Drug Administration without clinical postmarketing requirements or commitments. JAMA Netw Open. 2019;2(5):e193410. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.3410.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"610_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/1078-0432.CCR-23-2268","volume":"30","author":"G Collins","year":"2024","unstructured":"Collins G, McKelvey B, Andrews HS, Allen JD, Stewart MD. An analysis of dosing-related postmarketing requirements for novel oncology drugs approved by the U.S. Food and Drug Administration, 2012-2022. Clin Cancer Res. 2024;30(5):937\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2268.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"610_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/jcph.2208","volume":"63","author":"S Ridge","year":"2023","unstructured":"Ridge S, Guinn D, Pfuma Fletcher E, Zineh I, Madabushi R, Ramamoorthy A. US FDA postmarketing requirements and commitments: a systematic assessment of clinical pharmacology studies and their impact on US FDA prescribing information. J Clin Pharmacol. 2023;63(6):695\u2013703. https:\/\/doi.org\/10.1002\/jcph.2208.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"610_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.2701","volume":"112","author":"IR Younis","year":"2022","unstructured":"Younis IR, Manchandani P, Hassan HE, Qosa H. Trends in FDA transporter-based post-marketing requirements and commitments over the last decade. Clin Pharmacol Ther. 2022;112(3):635\u201342. https:\/\/doi.org\/10.1002\/cpt.2701.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"610_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53211-z","volume":"14","author":"N Markey","year":"2024","unstructured":"Markey N, Howitt B, El-Mansouri I, Schwartzenberg C, Kotova O, Meier C. Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials. Sci Rep. 2024;14(1):3514. https:\/\/doi.org\/10.1038\/s41598-024-53211-z.","journal-title":"Sci Rep"},{"issue":"3","key":"610_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s43441-025-00760-8","volume":"59","author":"S Abdel-Rahman","year":"2025","unstructured":"Abdel-Rahman S, Sund Z, Alderman C, Abella K, Kennel P, Best Pharmaceuticals for Children Act \u2013 Pediatric Trials Network Steering Committee. Sponsor- vs. FDA-initiated changes to pediatric clinical trial protocols: a comparison of associated participant burden. Ther Innov Regul Sci. 2025;59(3):558\u201365. https:\/\/doi.org\/10.1007\/s43441-025-00760-8.","journal-title":"Ther Innov Regul Sci"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1002\/jcph.1836","volume":"61","author":"SN Kalaria","year":"2021","unstructured":"Kalaria SN, Farchione TR, Uppoor R, Mehta M, Wang Y, Zhu H. Extrapolation of efficacy and dose selection in pediatrics: a case example of atypical antipsychotics in adolescents with Schizophrenia and Bipolar I Disorder. J Clin Pharmacol. 2021;61:S117-24. https:\/\/doi.org\/10.1002\/jcph.1836.","journal-title":"J Clin Pharmacol"},{"key":"610_CR22","unstructured":"Access to Medicines Foundation. Closing gaps in access to medicine for children: how R&D and delivery efforts can be ramped up. 2021. https:\/\/accesstomedicinefoundation.org\/resource\/closing-gaps-in-access-to-medicine-for-children-how-r-d-and-delivery-efforts-can-be-ramped-up. Accessed 11 Aug 2025."},{"issue":"3","key":"610_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41390-025-03923-3","volume":"98","author":"K Singh","year":"2025","unstructured":"Singh K, Franson T, McCune S, Jorgensen D, Getz K, Bearer C, et al. Breaking the silence: challenges and opportunities in pediatric drug development. Pediatr Res. 2025;98(3):807\u201312. https:\/\/doi.org\/10.1038\/s41390-025-03923-3.","journal-title":"Pediatr Res"},{"issue":"6","key":"610_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14060583","volume":"14","author":"D Selig","year":"2025","unstructured":"Selig D, Aminu F, Cammarata S, Chen T, Dolak L, Duprez S, et al. Landscape of post-marketing requirements under the Pediatric Research Equity Act for antibiotics from 2009-2024. Antibiotics Basel. 2025;14(6):583. https:\/\/doi.org\/10.3390\/antibiotics14060583.","journal-title":"Antibiotics Basel"},{"key":"610_CR25","unstructured":"U.S. Department of Health and Human Services. Grants.gov. https:\/\/grants.gov\/. Accessed 14 Aug 2025."},{"key":"610_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2025.103165","volume":"14","author":"M Bozzetti","year":"2025","unstructured":"Bozzetti M, Caruso R, Soncini S, Guberti M. Development of the clinical trial site performance metrics instrument: a study protocol. MethodsX. 2025;14:103165. https:\/\/doi.org\/10.1016\/j.mex.2025.103165.","journal-title":"MethodsX"},{"key":"610_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.conctc.2018.01.005","volume":"9","author":"E Yang","year":"2018","unstructured":"Yang E, O\u2019Donovan C, Phillips J, Atkinson L, Ghosh K, Agrafiotis DK. Quantifying and visualizing site performance in clinical trials. Contemp Clin Trials Commun. 2018;9:108\u201314. https:\/\/doi.org\/10.1016\/j.conctc.2018.01.005.","journal-title":"Contemp Clin Trials Commun"},{"issue":"6","key":"610_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.sapharm.2019.11.004","volume":"16","author":"DG Dauner","year":"2020","unstructured":"Dauner DG, Dauner KN, Peterson ALH. FDA\u2019s unimproved enforcement of postmarketing requirements and commitments: implications for providers and patients. Res Social Adm Pharm. 2020;16(6):844\u20137. https:\/\/doi.org\/10.1016\/j.sapharm.2019.11.004.","journal-title":"Res Social Adm Pharm"},{"issue":"14","key":"610_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMp2400699","volume":"391","author":"CJR Daval","year":"2024","unstructured":"Daval CJR, Kesselheim AS, Cliff ERS. Confirmatory trials of accelerated approval drugs - will imposing fines reduce delays? N Engl J Med. 2024;391(14):1273\u20135. https:\/\/doi.org\/10.1056\/NEJMp2400699.","journal-title":"N Engl J Med"},{"key":"610_CR30","unstructured":"U.S. Food and Drug Administration. Postmarketing studies and clinical trials: determining good cause for noncompliance with section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act. Draft guidance for industry. 2023. https:\/\/www.fda.gov\/media\/170187\/download. Accessed 10 Nov 2025."},{"issue":"3","key":"610_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002520","volume":"15","author":"TJ Hwang","year":"2018","unstructured":"Hwang TJ, Tomasi PA, Bourgeois FT. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: a cohort study. PLoS Med. 2018;15(3):e1002520. https:\/\/doi.org\/10.1371\/journal.pmed.1002520.","journal-title":"PLoS Med"},{"key":"610_CR32","unstructured":"U.S. Government Accountability Office. Drug safety: FDA expedites many applications, but data for postapproval oversight need improvement. 2016. http:\/\/www.gao.gov\/products\/GAO-16-192. Accessed 6 Aug 2025."},{"issue":"3","key":"610_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos S, Getz KA, Blazynski C. Evaluating the completeness of ClinicalTrials.gov. Ther Innov Regul Sci. 2019;53(3):307\u201317. https:\/\/doi.org\/10.1177\/2168479018782885.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00610-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:18:42Z","timestamp":1779970722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00610-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00610-4","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"15 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable; this article relies solely on data from the review of non-human subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Web links to publicly accessible data are provided within the body of the manuscript. Non-public, confidential data held at the FDA cannot be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SAR, LY and GB were involved in the conception and design of the study. SAR, NG, CC and YG were involved in the acquisition of the data. SAR, LY and GB were involved in the analysis and interpretation of data. SAR was responsible for performing the statistical analyses and drafting the original manuscript. All authors contributed to the critical revision of the manuscript, read and approve the final published version, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}